1
|
Aspnes GE, Bagley SW, Coffey SB, Conn EL, Curto JM, Edmonds DJ, Genovino J, Griffith DA, Ingle G, Jiao W, Limberakis C, Mathiowetz AM, Piotrowski DW, Rose CR, Ruggeri RB, Wei L. 6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor. Bioorg Med Chem Lett 2023; 94:129454. [PMID: 37591316 DOI: 10.1016/j.bmcl.2023.129454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Revised: 07/05/2023] [Accepted: 08/14/2023] [Indexed: 08/19/2023]
Abstract
Activation of the glucagon-like peptide-1 (GLP-1) receptor stimulates insulin release, lowers plasma glucose levels, delays gastric emptying, increases satiety, suppresses food intake, and affords weight loss in humans. These beneficial attributes have made peptide-based agonists valuable tools for the treatment of type 2 diabetes mellitus and obesity. However, efficient, and consistent delivery of peptide agents generally requires subcutaneous injection, which can reduce patient utilization. Traditional orally absorbed small molecules for this target may offer improved patient compliance as well as the opportunity for co-formulation with other oral therapeutics. Herein, we describe an SAR investigation leading to small-molecule GLP-1 receptor agonists that represent a series that parallels the recently reported clinical candidate danuglipron. In the event, identification of a benzyloxypyrimidine lead, using a sensitized high-throughput GLP-1 agonist assay, was followed by optimization of the SAR using substituent modifications analogous to those discovered in the danuglipron series. A new series of 6-azaspiro[2.5]octane molecules was optimized into potent GLP-1 agonists. Information gleaned from cryogenic electron microscope structures was used to rationalize the SAR of the optimized compounds.
Collapse
Affiliation(s)
- Gary E Aspnes
- Pfizer Medicine Design, Cambridge, MA 02139, United States
| | | | | | - Edward L Conn
- Pfizer Medicine Design, Groton, CT 06340, United States
| | - John M Curto
- Pfizer Medicine Design, Groton, CT 06340, United States
| | | | | | | | | | - Wenhua Jiao
- Pfizer Medicine Design, Groton, CT 06340, United States
| | | | | | | | - Colin R Rose
- Pfizer Medicine Design, Groton, CT 06340, United States
| | | | - Liuqing Wei
- Pfizer Medicine Design, Groton, CT 06340, United States
| |
Collapse
|
2
|
Acker BA, Badescu VO, Berkenpas MB, Groppi VE, Hajós M, Higdon NR, Hurst RS, Jon Jacobsen E, Margolis BJ, McWhorter WW, Myers JK, Piotrowski DW, Rogers BN, Sarapa D, Vetman TN, Walker DP, Wall TM, Wilhite DM, Wishka DG, Xu W, Yates KM. Positive allosteric modulators of the α7 nicotinic acetylcholine receptor: SAR investigation around PNU-120596. Bioorg Med Chem Lett 2023; 93:129433. [PMID: 37557923 DOI: 10.1016/j.bmcl.2023.129433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 06/17/2023] [Accepted: 08/03/2023] [Indexed: 08/11/2023]
Abstract
The α7 nicotinic acetylcholine receptor is a calcium permeable, ligand-gated ion channel that modulates synaptic transmission in the hippocampus, thalamus, and cerebral cortex. Previously disclosed work described PNU-120596 that acts as a powerful positive allosteric modulator of the α7 nicotinic acetylcholine receptor. The initial structure-activity relationships around PNU-120596 were gleaned from screening a large thiazole library. Independent systematic examination of the aryl and heteroaryl groups resulted in compounds with enhanced potency and improved physico-chemical properties culminating in the identification of 16 (PHA-758454). In the presence of acetylcholine, 16 enhanced evoked currents in rat hippocampal neurons. In a rat model of impaired sensory gating, treatment with 16 led to a reversal of the gating deficit in a dose-dependent manner. These results demonstrate that aryl heteroaryl ureas, like compound 16, may be useful tools for continued exploration of the unique biology of the α7 nicotinic acetylcholine receptor.
Collapse
Affiliation(s)
- Brad A Acker
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | | | | | | | - Mihaly Hajós
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - Nicole R Higdon
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - Raymond S Hurst
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - E Jon Jacobsen
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | | | | | - Jason K Myers
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | | | - Bruce N Rogers
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - Dusan Sarapa
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | | | - Daniel P Walker
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - Theron M Wall
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - David M Wilhite
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - Donn G Wishka
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - Wenjian Xu
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - Karen M Yates
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| |
Collapse
|
3
|
Aspnes GE, Coffey SB, Darout E, Dechert-Schmitt AM, Dullea RG, Kamlet AS, Limberakis C, Londregan AT, McClure KF, Menhaji-Klotz E, Piotrowski DW, Polivkova J, Raymer B, Ruggeri RB, Salatto CT, Tu M, Wei L, Xiao J. Small molecule inhibitors of PCSK9. SAR investigations of head and amine groups. Bioorg Med Chem Lett 2023:129394. [PMID: 37379958 DOI: 10.1016/j.bmcl.2023.129394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Revised: 06/02/2023] [Accepted: 06/24/2023] [Indexed: 06/30/2023]
Abstract
Our previous work on the optimization of a new class of small molecule PCSK9 mRNA translation inhibitors focused on empirical optimization of the amide tail region of the lead PF-06446846 (1). This work resulted in compound 3 that showed an improved safety profile. We hypothesized that this improvement was related to diminished binding of 3 to non-translating ribosomes and an apparent improvement in transcript selectivity. Herein, we describe our efforts to further optimize this series of inhibitors through modulation of the heterocyclic head group and the amine fragment. Some of the effort was guided by an emerging cryo electron microscopy structure of the binding mode of 1 in the ribosome. These efforts led to the identification of 15 that was deemed suitable for evaluation in a humanized PCSK9 mouse model and a rat toxicology study. Compound 15 demonstrated a dose dependent reduction of plasma PCSK9 levels. The rat toxicological profile was not improved over that of 1, which precluded 15 from further consideration as a clinical candidate.
Collapse
Affiliation(s)
- Gary E Aspnes
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| | - Steven B Coffey
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| | - Etzer Darout
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| | | | - Robert G Dullea
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| | - Adam S Kamlet
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| | - Chris Limberakis
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| | - Allyn T Londregan
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| | - Kim F McClure
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| | - Elnaz Menhaji-Klotz
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| | - David W Piotrowski
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA.
| | - Jana Polivkova
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| | - Brian Raymer
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| | - Roger B Ruggeri
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| | | | - Meihua Tu
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| | - Liuqing Wei
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| | - Jun Xiao
- Pfizer Medicine Design, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| |
Collapse
|
4
|
Baldwin A, Cabral S, Jones KN, Kohrt JT, Limberakis C, Liu Y, Magano J, Monfette S, Nematalla A, Ovaska S, Piotrowski DW, Piper JL, Raggon JW, Thuma BA, Wei L. Route Optimization of the Non-covalent Modulator of Hemoglobin PF-07059013 for the Treatment of Sickle Cell Disease, Part I: From Discovery Synthesis to First Kilogram-Scale Manufacture. Org Process Res Dev 2023. [DOI: 10.1021/acs.oprd.2c00351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Affiliation(s)
- Aaron Baldwin
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Shawn Cabral
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Kris N. Jones
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Jeffrey T. Kohrt
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Chris Limberakis
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Yiyang Liu
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Javier Magano
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Sebastien Monfette
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Asaad Nematalla
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Sami Ovaska
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - David W. Piotrowski
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Jared L. Piper
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Jeffrey W. Raggon
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Benjamin A. Thuma
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Liuqing Wei
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| |
Collapse
|
5
|
Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, Saxena AR, Bagley SW, Buckeridge C, Curto JM, Derksen DR, Dias JM, Griffor MC, Han S, Jackson VM, Landis MS, Lettiere D, Limberakis C, Liu Y, Mathiowetz AM, Patel JC, Piotrowski DW, Price DA, Ruggeri RB, Tess DA. A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor. J Med Chem 2022; 65:8208-8226. [PMID: 35647711 PMCID: PMC9234956 DOI: 10.1021/acs.jmedchem.1c01856] [Citation(s) in RCA: 31] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited because they require injection. Herein, we describe the discovery of the orally bioavailable, small-molecule, GLP-1R agonist PF-06882961 (danuglipron). A sensitized high-throughput screen was used to identify 5-fluoropyrimidine-based GLP-1R agonists that were optimized to promote endogenous GLP-1R signaling with nanomolar potency. Incorporation of a carboxylic acid moiety provided considerable GLP-1R potency gains with improved off-target pharmacology and reduced metabolic clearance, ultimately resulting in the identification of danuglipron. Danuglipron increased insulin levels in primates but not rodents, which was explained by receptor mutagensis studies and a cryogenic electron microscope structure that revealed a binding pocket requiring a primate-specific tryptophan 33 residue. Oral administration of danuglipron to healthy humans produced dose-proportional increases in systemic exposure (NCT03309241). This opens an opportunity for oral small-molecule therapies that target the well-validated GLP-1R for metabolic health.
Collapse
Affiliation(s)
- David A Griffith
- Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States
| | - David J Edmonds
- Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States
| | - Jean-Philippe Fortin
- Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States
| | - Amit S Kalgutkar
- Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States
| | - J Brent Kuzmiski
- Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States
| | - Paula M Loria
- Pfizer Worldwide Research, Development, and Medical, Groton, Connecticut 06340, United States
| | - Aditi R Saxena
- Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States
| | - Scott W Bagley
- Pfizer Worldwide Research, Development, and Medical, Groton, Connecticut 06340, United States
| | - Clare Buckeridge
- Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States
| | - John M Curto
- Pfizer Worldwide Research, Development, and Medical, Groton, Connecticut 06340, United States
| | - David R Derksen
- Pfizer Worldwide Research, Development, and Medical, Groton, Connecticut 06340, United States
| | - João M Dias
- Pfizer Worldwide Research, Development, and Medical, Groton, Connecticut 06340, United States
| | - Matthew C Griffor
- Pfizer Worldwide Research, Development, and Medical, Groton, Connecticut 06340, United States
| | - Seungil Han
- Pfizer Worldwide Research, Development, and Medical, Groton, Connecticut 06340, United States
| | - V Margaret Jackson
- Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States
| | - Margaret S Landis
- Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States
| | - Daniel Lettiere
- Pfizer Worldwide Research, Development, and Medical, Groton, Connecticut 06340, United States
| | - Chris Limberakis
- Pfizer Worldwide Research, Development, and Medical, Groton, Connecticut 06340, United States
| | - Yuhang Liu
- Pfizer Worldwide Research, Development, and Medical, Groton, Connecticut 06340, United States
| | - Alan M Mathiowetz
- Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States
| | | | - David W Piotrowski
- Pfizer Worldwide Research, Development, and Medical, Groton, Connecticut 06340, United States
| | - David A Price
- Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States
| | - Roger B Ruggeri
- Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States
| | - David A Tess
- Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
6
|
Knee KM, Jasuja R, Barakat A, Rao D, Wenzel Z, Jasti J, Novak J, Beaumont K, Piotrowski DW, Jeffrey P, Bulawa C, Murphy JE, Janz JM. PF-07059013: A non-covalent hemoglobin modulator favorably impacts disease state in a mouse model of sickle cell disease. Am J Hematol 2021; 96:E272-E275. [PMID: 33891711 PMCID: PMC8360071 DOI: 10.1002/ajh.26204] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Revised: 04/19/2021] [Accepted: 04/21/2021] [Indexed: 11/25/2022]
Affiliation(s)
- Kelly M. Knee
- Rare Disease Research Unit Pfizer Worldwide Research, Development, and Medical Cambridge Massachusetts USA
| | - Reema Jasuja
- Rare Disease Research Unit Pfizer Worldwide Research, Development, and Medical Cambridge Massachusetts USA
| | - Amey Barakat
- Rare Disease Research Unit Pfizer Worldwide Research, Development, and Medical Cambridge Massachusetts USA
| | - Dharani Rao
- Rare Disease Research Unit Pfizer Worldwide Research, Development, and Medical Cambridge Massachusetts USA
| | - Zane Wenzel
- Primary Pharmacology Group Pfizer Medicine Design, Pfizer Worldwide Research, Development and Medical Groton Connecticut USA
| | - Jayasankar Jasti
- Discovery Sciences Pfizer Worldwide Research, Development and Medical Groton Connecticut USA
| | - Jonathan Novak
- Pharmacokinetics, Dynamics, Metabolism, Pfizer Medicine Design, Pfizer Worldwide Research, Development and Medical Groton Connecticut USA
| | - Kevin Beaumont
- Pharmacokinetics, Dynamics, Metabolism, Pfizer Medicine Design, Pfizer Worldwide Research, Development and Medical Groton Connecticut USA
| | - David W. Piotrowski
- Pfizer Medicine Design Pfizer Worldwide Research, Development and Medical Groton Connecticut USA
| | - Phil Jeffrey
- Rare Disease Research Unit Pfizer Worldwide Research, Development, and Medical Cambridge Massachusetts USA
| | - Christine Bulawa
- Rare Disease Research Unit Pfizer Worldwide Research, Development, and Medical Cambridge Massachusetts USA
| | - John E. Murphy
- Rare Disease Research Unit Pfizer Worldwide Research, Development, and Medical Cambridge Massachusetts USA
| | - Jay M. Janz
- Rare Disease Research Unit Pfizer Worldwide Research, Development, and Medical Cambridge Massachusetts USA
| |
Collapse
|
7
|
Kinens A, Balkaitis S, Ahmad OK, Piotrowski DW, Suna E. Acylative Dynamic Kinetic Resolution of Secondary Alcohols: Tandem Catalysis by HyperBTM and Bäckvall's Ruthenium Complex. J Org Chem 2021; 86:7189-7202. [PMID: 33974415 DOI: 10.1021/acs.joc.1c00545] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Non-enzymatic dynamic kinetic resolution (DKR) of secondary alcohols by enantioselective acylation using an isothiourea-derived HyperBTM catalyst and racemization of slowly reacting alcohol by Bäckvall's ruthenium complex is reported. The DKR approach features high enantioselectivities (up to 99:1), employs easy-to-handle crystalline 4-nitrophenyl isobutyrate as the acylating reagent, and proceeds at room temperature and under an ambient atmosphere. The stereoinduction model featuring cation-π system interactions between the acylated HyperBTM catalyst and π electrons of an alcohol aryl subunit has been elaborated by DFT calculations.
Collapse
Affiliation(s)
- Artis Kinens
- Latvian Institute of Organic Synthesis, Aizkraukles 21, Riga LV-1006, Latvia.,Department of Chemistry, University of Latvia, Jelgavas 1, Riga LV-1004, Latvia
| | - Simonas Balkaitis
- Latvian Institute of Organic Synthesis, Aizkraukles 21, Riga LV-1006, Latvia.,Department of Chemistry, University of Latvia, Jelgavas 1, Riga LV-1004, Latvia
| | - Omar K Ahmad
- Worldwide Medicinal Chemistry, Pfizer, Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - David W Piotrowski
- Worldwide Medicinal Chemistry, Pfizer, Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Edgars Suna
- Latvian Institute of Organic Synthesis, Aizkraukles 21, Riga LV-1006, Latvia.,Department of Chemistry, University of Latvia, Jelgavas 1, Riga LV-1004, Latvia
| |
Collapse
|
8
|
Gopalsamy A, Aulabaugh AE, Barakat A, Beaumont KC, Cabral S, Canterbury DP, Casimiro-Garcia A, Chang JS, Chen MZ, Choi C, Dow RL, Fadeyi OO, Feng X, France SP, Howard RM, Janz JM, Jasti J, Jasuja R, Jones LH, King-Ahmad A, Knee KM, Kohrt JT, Limberakis C, Liras S, Martinez CA, McClure KF, Narayanan A, Narula J, Novak JJ, O'Connell TN, Parikh MD, Piotrowski DW, Plotnikova O, Robinson RP, Sahasrabudhe PV, Sharma R, Thuma BA, Vasa D, Wei L, Wenzel AZ, Withka JM, Xiao J, Yayla HG. PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease. J Med Chem 2020; 64:326-342. [PMID: 33356244 DOI: 10.1021/acs.jmedchem.0c01518] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Sickle cell disease (SCD) is a genetic disorder caused by a single point mutation (β6 Glu → Val) on the β-chain of adult hemoglobin (HbA) that results in sickled hemoglobin (HbS). In the deoxygenated state, polymerization of HbS leads to sickling of red blood cells (RBC). Several downstream consequences of polymerization and RBC sickling include vaso-occlusion, hemolytic anemia, and stroke. We report the design of a noncovalent modulator of HbS, clinical candidate PF-07059013 (23). The seminal hit molecule was discovered by virtual screening and confirmed through a series of biochemical and biophysical studies. After a significant optimization effort, we arrived at 23, a compound that specifically binds to Hb with nanomolar affinity and displays strong partitioning into RBCs. In a 2-week multiple dose study using Townes SCD mice, 23 showed a 37.8% (±9.0%) reduction in sickling compared to vehicle treated mice. 23 (PF-07059013) has advanced to phase 1 clinical trials.
Collapse
Affiliation(s)
- Ariamala Gopalsamy
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Ann E Aulabaugh
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Amey Barakat
- Rare Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Kevin C Beaumont
- Primary Pharmacology Group, Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Shawn Cabral
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Daniel P Canterbury
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Agustin Casimiro-Garcia
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Jeanne S Chang
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Ming Z Chen
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Chulho Choi
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Robert L Dow
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Olugbeminiyi O Fadeyi
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Xidong Feng
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Scott P France
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Roger M Howard
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Jay M Janz
- Rare Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Jayasankar Jasti
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Reema Jasuja
- Rare Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Lyn H Jones
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Amanda King-Ahmad
- Primary Pharmacology Group, Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Kelly M Knee
- Rare Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Jeffrey T Kohrt
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Chris Limberakis
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Spiros Liras
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Carlos A Martinez
- Medicinal Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Kim F McClure
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Arjun Narayanan
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Jatin Narula
- Primary Pharmacology Group, Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Jonathan J Novak
- Primary Pharmacology Group, Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Thomas N O'Connell
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Mihir D Parikh
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - David W Piotrowski
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Olga Plotnikova
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Ralph P Robinson
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Parag V Sahasrabudhe
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Raman Sharma
- Primary Pharmacology Group, Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Benjamin A Thuma
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Dipy Vasa
- Drug Product Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Liuqing Wei
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - A Zane Wenzel
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Jane M Withka
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Jun Xiao
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Hatice G Yayla
- Pfizer Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| |
Collapse
|
9
|
Fan Z, Zhao S, Liu T, Shen PX, Cui ZN, Zhuang Z, Shao Q, Chen JS, Ratnayake AS, Flanagan ME, Kölmel DK, Piotrowski DW, Richardson P, Yu JQ. Merging C(sp 3)-H activation with DNA-encoding. Chem Sci 2020; 11:12282-12288. [PMID: 34094436 PMCID: PMC8162953 DOI: 10.1039/d0sc03935g] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
DNA-encoded library (DEL) technology has the potential to dramatically expedite hit identification in drug discovery owing to its ability to perform protein affinity selection with millions or billions of molecules in a few experiments. To expand the molecular diversity of DEL, it is critical to develop different types of DNA-encoded transformations that produce billions of molecules with distinct molecular scaffolds. Sequential functionalization of multiple C–H bonds provides a unique avenue for creating diversity and complexity from simple starting materials. However, the use of water as solvent, the presence of DNA, and the extremely low concentration of DNA-encoded coupling partners (0.001 M) have hampered the development of DNA-encoded C(sp3)–H activation reactions. Herein, we report the realization of palladium-catalyzed C(sp3)–H arylation of aliphatic carboxylic acids, amides and ketones with DNA-encoded aryl iodides in water. Notably, the present method enables the use of alternative sets of monofunctional building blocks, providing a linchpin to facilitate further setup for DELs. Furthermore, the C–H arylation chemistry enabled the on-DNA synthesis of structurally-diverse scaffolds containing enriched C(sp3) character, chiral centers, cyclopropane, cyclobutane, and heterocycles. DNA-compatible C(sp3)–H activation reactions of aliphatic carboxylic acids, amides, and ketones were developed for efficient access to DEL synthesis.![]()
Collapse
Affiliation(s)
- Zhoulong Fan
- Department of Chemistry, The Scripps Research Institute 10550 North Torrey Pines Road, La Jolla CA 92037 USA
| | - Shuai Zhao
- Department of Chemistry, The Scripps Research Institute 10550 North Torrey Pines Road, La Jolla CA 92037 USA
| | - Tao Liu
- Department of Chemistry, The Scripps Research Institute 10550 North Torrey Pines Road, La Jolla CA 92037 USA
| | - Peng-Xiang Shen
- Department of Chemistry, The Scripps Research Institute 10550 North Torrey Pines Road, La Jolla CA 92037 USA
| | - Zi-Ning Cui
- Department of Chemistry, The Scripps Research Institute 10550 North Torrey Pines Road, La Jolla CA 92037 USA
| | - Zhe Zhuang
- Department of Chemistry, The Scripps Research Institute 10550 North Torrey Pines Road, La Jolla CA 92037 USA
| | - Qian Shao
- Department of Chemistry, The Scripps Research Institute 10550 North Torrey Pines Road, La Jolla CA 92037 USA
| | - Jason S Chen
- Automated Synthesis Facility, The Scripps Research Institute 10550 North Torrey Pines Road, La Jolla CA 92037 USA
| | - Anokha S Ratnayake
- Pfizer Medicinal Chemistry Eastern Point Road, Groton Connecticut 06340 USA
| | - Mark E Flanagan
- Pfizer Medicinal Chemistry Eastern Point Road, Groton Connecticut 06340 USA
| | - Dominik K Kölmel
- Pfizer Medicinal Chemistry Eastern Point Road, Groton Connecticut 06340 USA
| | - David W Piotrowski
- Pfizer Medicinal Chemistry Eastern Point Road, Groton Connecticut 06340 USA
| | - Paul Richardson
- Pfizer Medicinal Chemistry, 10578 Science Center Drive San Diego CA 09121 USA
| | - Jin-Quan Yu
- Department of Chemistry, The Scripps Research Institute 10550 North Torrey Pines Road, La Jolla CA 92037 USA
| |
Collapse
|
10
|
Matos JLM, Green SA, Chun Y, Dang VQ, Dushin RG, Richardson P, Chen JS, Piotrowski DW, Paegel BM, Shenvi RA. Cycloisomerization of Olefins in Water. Angew Chem Int Ed Engl 2020; 59:12998-13003. [PMID: 32285542 DOI: 10.1002/anie.202003948] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Indexed: 11/11/2022]
Abstract
Preparative reactions that occur efficiently under dilute, buffered, aqueous conditions in the presence of biomolecules find application in ligation, peptide synthesis, and polynucleotide synthesis and sequencing. However, the identification of functional groups or reagents that are mutually reactive with one another, but unreactive with biopolymers and water, is challenging. Shown here are cobalt catalysts that react with alkenes under dilute, aqueous, buffered conditions and promote efficient cycloisomerization and formal Friedel-Crafts reactions. The constraining conditions of bioorthogonal chemistry are beneficial for reaction efficiency as superior conversion at low catalyst concentration is obtained and competent rates in dilute conditions are maintained. Efficiency at high dilution in the presence of buffer and nucleobases suggests that these reaction conditions may find broad application.
Collapse
Affiliation(s)
- Jeishla L M Matos
- Department of Chemistry, Scripps Research, 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Samantha A Green
- Department of Chemistry, Scripps Research, 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Yuge Chun
- Department of Chemistry, Scripps Research, 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Vuong Q Dang
- Department of Pharmaceutical Sciences, University of California Irvine, 101 Theory, Suite 100, Irvine, CA, 92617, USA
| | - Russell G Dushin
- Pfizer Medicinal Chemistry, Eastern Point Road, Groton, CT, 06340, USA
| | - Paul Richardson
- Pfizer Medicinal Chemistry, 10578 Science Center Drive, San Diego, CA, 92121, USA
| | - Jason S Chen
- Automated Synthesis Facility, Scripps Research, 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA
| | | | - Brian M Paegel
- Department of Pharmaceutical Sciences, University of California Irvine, 101 Theory, Suite 100, Irvine, CA, 92617, USA.,Departments of Chemistry & Biomedical Engineering, University of California Irvine, 101 Theory, Suite 100, Irvine, CA, 92617, USA
| | - Ryan A Shenvi
- Department of Chemistry, Scripps Research, 10550 North Torrey Pines Road, La Jolla, CA, 92037, USA
| |
Collapse
|
11
|
Matos JLM, Green SA, Chun Y, Dang VQ, Dushin RG, Richardson P, Chen JS, Piotrowski DW, Paegel BM, Shenvi RA. Cycloisomerization of Olefins in Water. Angew Chem Int Ed Engl 2020. [DOI: 10.1002/ange.202003948] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Jeishla L. M. Matos
- Department of Chemistry Scripps Research 10550 North Torrey Pines Road La Jolla CA 92037 USA
| | - Samantha A. Green
- Department of Chemistry Scripps Research 10550 North Torrey Pines Road La Jolla CA 92037 USA
| | - Yuge Chun
- Department of Chemistry Scripps Research 10550 North Torrey Pines Road La Jolla CA 92037 USA
| | - Vuong Q. Dang
- Department of Pharmaceutical Sciences University of California Irvine 101 Theory, Suite 100 Irvine CA 92617 USA
| | | | - Paul Richardson
- Pfizer Medicinal Chemistry 10578 Science Center Drive San Diego CA 92121 USA
| | - Jason S. Chen
- Automated Synthesis Facility Scripps Research 10550 North Torrey Pines Road La Jolla CA 92037 USA
| | | | - Brian M. Paegel
- Department of Pharmaceutical Sciences University of California Irvine 101 Theory, Suite 100 Irvine CA 92617 USA
- Departments of Chemistry & Biomedical Engineering University of California Irvine 101 Theory, Suite 100 Irvine CA 92617 USA
| | - Ryan A. Shenvi
- Department of Chemistry Scripps Research 10550 North Torrey Pines Road La Jolla CA 92037 USA
| |
Collapse
|
12
|
Flood DT, Zhang X, Fu X, Zhao Z, Asai S, Sanchez BB, Sturgell EJ, Vantourout JC, Richardson P, Flanagan ME, Piotrowski DW, Kölmel DK, Wan J, Tsai MH, Chen JS, Baran PS, Dawson PE. RASS-Enabled S/P-C and S-N Bond Formation for DEL Synthesis. Angew Chem Int Ed Engl 2020; 59:7377-7383. [PMID: 32050046 DOI: 10.1002/anie.201915493] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2019] [Revised: 01/05/2020] [Indexed: 01/28/2023]
Abstract
DNA encoded libraries (DEL) have shown promise as a valuable technology for democratizing the hit discovery process. Although DEL provides relatively inexpensive access to libraries of unprecedented size, their production has been hampered by the idiosyncratic needs of the encoding DNA tag relegating DEL compatible chemistry to dilute aqueous environments. Recently reversible adsorption to solid support (RASS) has been demonstrated as a promising method to expand DEL reactivity using standard organic synthesis protocols. Here we demonstrate a suite of on-DNA chemistries to incorporate medicinally relevant and C-S, C-P and N-S linkages into DELs, which are underrepresented in the canonical methods.
Collapse
Affiliation(s)
- Dillon T Flood
- Department of Chemistry, Scripps Research, 10550 N. Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Xuejing Zhang
- Department of Chemistry, Scripps Research, 10550 N. Torrey Pines Road, La Jolla, CA, 92037, USA.,School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China
| | - Xiang Fu
- Department of Chemistry, Scripps Research, 10550 N. Torrey Pines Road, La Jolla, CA, 92037, USA.,School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China
| | - Zhenxiang Zhao
- Department of Chemistry, Scripps Research, 10550 N. Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Shota Asai
- Department of Chemistry and Biological Sciences, Faculty of and Engineering, Iwate University, 4-3-5 Ueda, Morioka, 020-8551, Japan
| | - Brittany B Sanchez
- Automated Synthesis Facility, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Emily J Sturgell
- Automated Synthesis Facility, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Julien C Vantourout
- Department of Chemistry, Scripps Research, 10550 N. Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Paul Richardson
- Pfizer Medicinal Chemistry, 10770 Science Center Drive, San Diego, CA, 92121, USA
| | - Mark E Flanagan
- Pfizer Medicinal Chemistry, Eastern Point Road, Groton, CT, 06340, USA
| | | | - Dominik K Kölmel
- Pfizer Medicinal Chemistry, Eastern Point Road, Groton, CT, 06340, USA
| | - Jinqiao Wan
- HitGen Inc., Building 6, No. 8 Huigu 1st East Road Tianfu International Bio-Town, Shuangliu District, Chengdu, 610200, Sichuan, China
| | - Mei-Hsuan Tsai
- HitGen Inc., Building 6, No. 8 Huigu 1st East Road Tianfu International Bio-Town, Shuangliu District, Chengdu, 610200, Sichuan, China
| | - Jason S Chen
- Automated Synthesis Facility, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Phil S Baran
- Department of Chemistry, Scripps Research, 10550 N. Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Philip E Dawson
- Department of Chemistry, Scripps Research, 10550 N. Torrey Pines Road, La Jolla, CA, 92037, USA
| |
Collapse
|
13
|
Flood DT, Zhang X, Fu X, Zhao Z, Asai S, Sanchez BB, Sturgell EJ, Vantourout JC, Richardson P, Flanagan ME, Piotrowski DW, Kölmel DK, Wan J, Tsai M, Chen JS, Baran PS, Dawson PE. RASS‐Enabled S/P−C and S−N Bond Formation for DEL Synthesis. Angew Chem Int Ed Engl 2020. [DOI: 10.1002/ange.201915493] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Dillon T. Flood
- Department of ChemistryScripps Research 10550 N. Torrey Pines Road La Jolla CA 92037 USA
| | - Xuejing Zhang
- Department of ChemistryScripps Research 10550 N. Torrey Pines Road La Jolla CA 92037 USA
- School of Pharmaceutical SciencesSun Yat-sen University Guangzhou 510006 China
| | - Xiang Fu
- Department of ChemistryScripps Research 10550 N. Torrey Pines Road La Jolla CA 92037 USA
- School of Pharmaceutical SciencesSun Yat-sen University Guangzhou 510006 China
| | - Zhenxiang Zhao
- Department of ChemistryScripps Research 10550 N. Torrey Pines Road La Jolla CA 92037 USA
| | - Shota Asai
- Department of Chemistry and Biological SciencesFaculty of and EngineeringIwate University 4-3-5 Ueda Morioka 020-8551 Japan
| | - Brittany B. Sanchez
- Automated Synthesis FacilityThe Scripps Research Institute 10550 N. Torrey Pines Road La Jolla CA 92037 USA
| | - Emily J. Sturgell
- Automated Synthesis FacilityThe Scripps Research Institute 10550 N. Torrey Pines Road La Jolla CA 92037 USA
| | - Julien C. Vantourout
- Department of ChemistryScripps Research 10550 N. Torrey Pines Road La Jolla CA 92037 USA
| | - Paul Richardson
- Pfizer Medicinal Chemistry 10770 Science Center Drive San Diego CA 92121 USA
| | - Mark E. Flanagan
- Pfizer Medicinal Chemistry Eastern Point Road Groton CT 06340 USA
| | | | | | - Jinqiao Wan
- HitGen Inc. Building 6, No. 8 Huigu 1st East Road Tianfu International Bio-Town, Shuangliu District, Chengdu 610200 Sichuan China
| | - Mei‐Hsuan Tsai
- HitGen Inc. Building 6, No. 8 Huigu 1st East Road Tianfu International Bio-Town, Shuangliu District, Chengdu 610200 Sichuan China
| | - Jason S. Chen
- Automated Synthesis FacilityThe Scripps Research Institute 10550 N. Torrey Pines Road La Jolla CA 92037 USA
| | - Phil S. Baran
- Department of ChemistryScripps Research 10550 N. Torrey Pines Road La Jolla CA 92037 USA
| | - Philip E. Dawson
- Department of ChemistryScripps Research 10550 N. Torrey Pines Road La Jolla CA 92037 USA
| |
Collapse
|
14
|
Flood DT, Asai S, Zhang X, Wang J, Yoon L, Adams ZC, Dillingham BC, Sanchez BB, Vantourout JC, Flanagan ME, Piotrowski DW, Richardson P, Green SA, Shenvi RA, Chen JS, Baran PS, Dawson PE. Expanding Reactivity in DNA-Encoded Library Synthesis via Reversible Binding of DNA to an Inert Quaternary Ammonium Support. J Am Chem Soc 2019; 141:9998-10006. [PMID: 31136164 PMCID: PMC7033622 DOI: 10.1021/jacs.9b03774] [Citation(s) in RCA: 102] [Impact Index Per Article: 20.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
DNA Encoded Libraries have proven immensely powerful tools for lead identification. The ability to screen billions of compounds at once has spurred increasing interest in DEL development and utilization. Although DEL provides access to libraries of unprecedented size and diversity, the idiosyncratic and hydrophilic nature of the DNA tag severely limits the scope of applicable chemistries. It is known that biomacromolecules can be reversibly, noncovalently adsorbed and eluted from solid supports, and this phenomenon has been utilized to perform synthetic modification of biomolecules in a strategy we have described as reversible adsorption to solid support (RASS). Herein, we present the adaptation of RASS for a DEL setting, which allows reactions to be performed in organic solvents at near anhydrous conditions opening previously inaccessible chemical reactivities to DEL. The RASS approach enabled the rapid development of C(sp2)-C(sp3) decarboxylative cross-couplings with broad substrate scope, an electrochemical amination (the first electrochemical synthetic transformation performed in a DEL context), and improved reductive amination conditions. The utility of these reactions was demonstrated through a DEL-rehearsal in which all newly developed chemistries were orchestrated to afford a compound rich in diverse skeletal linkages. We believe that RASS will offer expedient access to new DEL reactivities, expanded chemical space, and ultimately more drug-like libraries.
Collapse
Affiliation(s)
- Dillon T. Flood
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Shota Asai
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Xuejing Zhang
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Jie Wang
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Leonard Yoon
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Zoë C. Adams
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Blythe C. Dillingham
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Brittany B. Sanchez
- Automated Synthesis Facility, Scripps Research, 10550 North Torrey Pines Road, La Jolla, CA 92037, United States
| | - Julien C. Vantourout
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Mark E. Flanagan
- Pfizer Medicinal Chemistry, Eastern Point Road, Groton, CT 06340, United States
| | - David W. Piotrowski
- Pfizer Medicinal Chemistry, Eastern Point Road, Groton, CT 06340, United States
| | - Paul Richardson
- Pfizer Medicinal Chemistry, 10578 Science Center Drive, San Diego, CA 92121, United States
| | - Samantha A. Green
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Ryan A. Shenvi
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Jason S. Chen
- Automated Synthesis Facility, Scripps Research, 10550 North Torrey Pines Road, La Jolla, CA 92037, United States
| | - Phil S. Baran
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Philip E. Dawson
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| |
Collapse
|
15
|
Akin A, Barilla MT, Brandt TA, Brennan J, Henegar KE, Hoagland S, Kumar R, Magano J, McInturff EL, Nematalla A, Piotrowski DW, Van Haitsma J, Wei L, Xiao J, Yu S. Overcoming the Challenges of Making a Single Enantiomer N-1 Substituted Tetrazole Prodrug Using a Tin-Mediated Alkylation and Enzymatic Resolution. Org Process Res Dev 2019. [DOI: 10.1021/acs.oprd.9b00104] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
16
|
Sun H, Piotrowski DW, Orr STM, Warmus JS, Wolford AC, Coffey SB, Futatsugi K, Zhang Y, Vaz ADN. Deuterium isotope effects in drug pharmacokinetics II: Substrate-dependence of the reaction mechanism influences outcome for cytochrome P450 cleared drugs. PLoS One 2018; 13:e0206279. [PMID: 30427871 PMCID: PMC6235261 DOI: 10.1371/journal.pone.0206279] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2018] [Accepted: 10/10/2018] [Indexed: 12/13/2022] Open
Abstract
Two chemotypes were examined in vitro with CYPs 3A4 and 2C19 by molecular docking, metabolic profiles, and intrinsic clearance deuterium isotope effects with specifically deuterated form to assess the potential for enhancement of pharmacokinetic parameters. The results show the complexity of deuteration as an approach for pharmacokinetic enhancement when CYP enzymes are involved in metabolic clearance. With CYP3A4 the rate limiting step was chemotype-dependent. With one chemotype no intrinsic clearance deuterium isotope effect was observed with any deuterated form, whereas with the other chemotype the rate limiting step was isotopically sensitive, and the magnitude of the intrinsic clearance isotope effect was dependent on the position(s) and extent of deuteration. Molecular docking and metabolic profiles aided in identifying sites for deuteration and predicted the possibility for metabolic switching. However, the potential for an isotope effect on the intrinsic clearance cannot be predicted and must be established by examining select deuterated versions of the chemotypes. The results show how in a deuteration strategy molecular docking, in-vitro metabolic profiles, and intrinsic clearance assessments with select deuterated versions of new chemical entities can be applied to determine the potential for pharmacokinetic enhancement in a discovery setting. They also help explain the substantial failures reported in the literature of deuterated versions of drugs to elicit a systemic enhancement on pharmacokinetic parameters.
Collapse
Affiliation(s)
- Hao Sun
- Medicine Design, Pfizer Global Research and Development, Groton, Connecticut, United States of America
- * E-mail: (DWP); (HS); (ADNV)
| | - David W. Piotrowski
- Medicine Design, Pfizer Global Research and Development, Groton, Connecticut, United States of America
- * E-mail: (DWP); (HS); (ADNV)
| | - Suvi T. M. Orr
- Medicine Design, Pfizer Global Research and Development, Groton, Connecticut, United States of America
| | - Joseph S. Warmus
- Medicine Design, Pfizer Global Research and Development, Groton, Connecticut, United States of America
| | - Angela C. Wolford
- Medicine Design, Pfizer Global Research and Development, Groton, Connecticut, United States of America
| | - Steven B. Coffey
- Medicine Design, Pfizer Global Research and Development, Groton, Connecticut, United States of America
| | - Kentaro Futatsugi
- Medicine Design, Pfizer Global Research and Development, Groton, Connecticut, United States of America
| | - Yinsheng Zhang
- Medicine Design, Pfizer Global Research and Development, Groton, Connecticut, United States of America
| | - Alfin D. N. Vaz
- Medicine Design, Pfizer Global Research and Development, Groton, Connecticut, United States of America
- * E-mail: (DWP); (HS); (ADNV)
| |
Collapse
|
17
|
Londregan AT, Aspnes G, Limberakis C, Loria PM, McClure KF, Petersen DN, Raymer B, Ruggeri RB, Wei L, Xiao J, Piotrowski DW. Discovery of N-(piperidin-3-yl)-N-(pyridin-2-yl)piperidine/piperazine-1-carboxamides as small molecule inhibitors of PCSK9. Bioorg Med Chem Lett 2018; 28:3685-3688. [PMID: 30482620 DOI: 10.1016/j.bmcl.2018.10.029] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Revised: 10/17/2018] [Accepted: 10/20/2018] [Indexed: 02/02/2023]
Abstract
A series of N-(piperidin-3-yl)-N-(pyridin-2-yl)piperidine/piperazine-1-carboxamides were identified as small molecule PCSK9 mRNA translation inhibitors. Analogues from this new chemical series, such as 4d and 4g, exhibited improved PCSK9 potency, ADME properties, and in vitro safety profiles when compared to earlier lead structures.
Collapse
Affiliation(s)
- Allyn T Londregan
- Pfizer Medicinal Chemistry, Pfizer Inc., Eastern Point Road, Groton, CT 06340, United States.
| | - Gary Aspnes
- Pfizer Medicinal Chemistry, Pfizer Inc., Eastern Point Road, Groton, CT 06340, United States
| | - Chris Limberakis
- Pfizer Medicinal Chemistry, Pfizer Inc., Eastern Point Road, Groton, CT 06340, United States
| | - Paula M Loria
- Pfizer Medicinal Chemistry, Pfizer Inc., Eastern Point Road, Groton, CT 06340, United States
| | - Kim F McClure
- Pfizer Medicinal Chemistry, Pfizer Inc., Eastern Point Road, Groton, CT 06340, United States
| | - Donna N Petersen
- Pfizer Medicinal Chemistry, Pfizer Inc., Eastern Point Road, Groton, CT 06340, United States
| | - Brian Raymer
- Pfizer Medicinal Chemistry, Pfizer Inc., Eastern Point Road, Groton, CT 06340, United States
| | - Roger B Ruggeri
- Pfizer Medicinal Chemistry, Pfizer Inc., Eastern Point Road, Groton, CT 06340, United States
| | - Liuqing Wei
- Pfizer Medicinal Chemistry, Pfizer Inc., Eastern Point Road, Groton, CT 06340, United States
| | - Jun Xiao
- Pfizer Medicinal Chemistry, Pfizer Inc., Eastern Point Road, Groton, CT 06340, United States
| | - David W Piotrowski
- Pfizer Medicinal Chemistry, Pfizer Inc., Eastern Point Road, Groton, CT 06340, United States
| |
Collapse
|
18
|
Londregan AT, Wei L, Xiao J, Lintner NG, Petersen D, Dullea RG, McClure KF, Bolt MW, Warmus JS, Coffey SB, Limberakis C, Genovino J, Thuma BA, Hesp KD, Aspnes GE, Reidich B, Salatto CT, Chabot JR, Cate JHD, Liras S, Piotrowski DW. Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents. J Med Chem 2018; 61:5704-5718. [DOI: 10.1021/acs.jmedchem.8b00650] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Affiliation(s)
| | - Liuqing Wei
- Pfizer Medicinal Chemistry, Groton, Connecticut 06340, United States
| | - Jun Xiao
- Pfizer Medicinal Chemistry, Groton, Connecticut 06340, United States
| | - Nathanael G. Lintner
- Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California 94720, United States
| | - Donna Petersen
- Primary Pharmacology Group, Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Robert G. Dullea
- Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Kim F. McClure
- Pfizer Medicinal Chemistry, Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Michael W. Bolt
- Drug Safety Research & Development, Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Joseph S. Warmus
- Pfizer Medicinal Chemistry, Groton, Connecticut 06340, United States
| | - Steven B. Coffey
- Pfizer Medicinal Chemistry, Groton, Connecticut 06340, United States
| | - Chris Limberakis
- Pfizer Medicinal Chemistry, Groton, Connecticut 06340, United States
| | - Julien Genovino
- Pfizer Medicinal Chemistry, Groton, Connecticut 06340, United States
| | - Benjamin A. Thuma
- Pfizer Medicinal Chemistry, Groton, Connecticut 06340, United States
| | - Kevin D. Hesp
- Pfizer Medicinal Chemistry, Groton, Connecticut 06340, United States
| | - Gary E. Aspnes
- Pfizer Medicinal Chemistry, Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Benjamin Reidich
- Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Christopher T. Salatto
- Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Jeffrey R. Chabot
- Pfizer Pharmacokinetics, Dynamics and Metabolism Modeling and Simulation, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | - Jamie H. D. Cate
- Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California 94720, United States
- QB3 Institute, University of California, Berkeley, Berkeley, California 94720, United States
- Department of Chemistry, University of California, Berkeley, Berkeley, California 94720, United States
- Physical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States
| | - Spiros Liras
- Pfizer Medicinal Chemistry, Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States
| | | |
Collapse
|
19
|
Lintner NG, McClure KF, Petersen D, Londregan AT, Piotrowski DW, Wei L, Xiao J, Bolt M, Loria PM, Maguire B, Geoghegan KF, Huang A, Rolph T, Liras S, Doudna JA, Dullea RG, Cate JHD. Correction: Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biol 2018; 16:e1002628. [PMID: 29664898 PMCID: PMC5903592 DOI: 10.1371/journal.pbio.1002628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
20
|
Menhaji-Klotz E, Hesp KD, Londregan AT, Kalgutkar AS, Piotrowski DW, Boehm M, Song K, Ryder T, Beaumont K, Jones RM, Atkinson K, Brown JA, Litchfield J, Xiao J, Canterbury DP, Burford K, Thuma BA, Limberakis C, Jiao W, Bagley SW, Agarwal S, Crowell D, Pazdziorko S, Ward J, Price DA, Clerin V. Discovery of a Novel Small-Molecule Modulator of C–X–C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis. J Med Chem 2018; 61:3685-3696. [DOI: 10.1021/acs.jmedchem.8b00190] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Affiliation(s)
- Elnaz Menhaji-Klotz
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Kevin D. Hesp
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Allyn T. Londregan
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Amit S. Kalgutkar
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - David W. Piotrowski
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Markus Boehm
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Kun Song
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Tim Ryder
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Kevin Beaumont
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Rhys M. Jones
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Karen Atkinson
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Janice A. Brown
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - John Litchfield
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Jun Xiao
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Daniel P. Canterbury
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Kristen Burford
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Benjamin A. Thuma
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Chris Limberakis
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Wenhua Jiao
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Scott W. Bagley
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Saket Agarwal
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Danielle Crowell
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Stephen Pazdziorko
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Jessica Ward
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - David A. Price
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Valerie Clerin
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
21
|
Piotrowski DW, Futatsugi K, Casimiro-Garcia A, Wei L, Sammons MF, Herr M, Jiao W, Lavergne SY, Coffey SB, Wright SW, Song K, Loria PM, Banker ME, Petersen DN, Bauman J. Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists. J Med Chem 2018; 61:1086-1097. [PMID: 29300474 DOI: 10.1021/acs.jmedchem.7b01515] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
A novel series of morpholine-based nonsteroidal mineralocorticoid receptor antagonists is reported. Starting from a pyrrolidine HTS hit 9 that possessed modest potency but excellect selectivity versus related nuclear hormone receptors, a series of libraries led to identification of morpholine lead 10. After further optimization, cis disubstituted morpholine 22 was discovered, which showed a 45-fold boost in binding affinity and corresponding functional potency compared to 13. While 22 had high clearance in rat, it provided sufficient exposure at high doses to favorably assess in vivo efficacy (increased urinary Na+/K+ ratio) and safety. In contrast to rat, the dog and human MetID and PK profiles of 22 were adequate, suggesting that it could be suitable as a potential clinical asset.
Collapse
Affiliation(s)
- David W Piotrowski
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Kentaro Futatsugi
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | | | - Liuqing Wei
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Matthew F Sammons
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Michael Herr
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Wenhua Jiao
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Sophie Y Lavergne
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Steven B Coffey
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Stephen W Wright
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Kun Song
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Paula M Loria
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Mary Ellen Banker
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Donna N Petersen
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| | - Jonathan Bauman
- Pfizer Research and Development , Groton, Connecticut 06340, United States
| |
Collapse
|
22
|
McClure KF, Piotrowski DW, Petersen D, Wei L, Xiao J, Londregan AT, Kamlet AS, Dechert-Schmitt AM, Raymer B, Ruggeri RB, Canterbury D, Limberakis C, Liras S, DaSilva-Jardine P, Dullea RG, Loria PM, Reidich B, Salatto CT, Eng H, Kimoto E, Atkinson K, King-Ahmad A, Scott D, Beaumont K, Chabot JR, Bolt MW, Maresca K, Dahl K, Arakawa R, Takano A, Halldin C. Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis. Angew Chem Int Ed Engl 2017. [DOI: 10.1002/ange.201708744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Kim F. McClure
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - David W. Piotrowski
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Donna Petersen
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Liuqing Wei
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Jun Xiao
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Allyn T. Londregan
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Adam S. Kamlet
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | | | - Brian Raymer
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Roger B. Ruggeri
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Daniel Canterbury
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Chris Limberakis
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Spiros Liras
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | | | - Robert G. Dullea
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Paula M. Loria
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Benjamin Reidich
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | | | - Heather Eng
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Emi Kimoto
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Karen Atkinson
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Amanda King-Ahmad
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Dennis Scott
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Kevin Beaumont
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Jeffrey R. Chabot
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Michael W. Bolt
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Kevin Maresca
- Department of Medicinal Chemistry, Pfizer Inc; 1 Portland Street Cambridge MA 02139 USA
| | - Kenneth Dahl
- Department of Clinical Neuroscience; Center for Psychiatry Research; Karolinska Institutet; Stockholm Sweden
| | - Ryosuke Arakawa
- Department of Clinical Neuroscience; Center for Psychiatry Research; Karolinska Institutet; Stockholm Sweden
| | - Akihiro Takano
- Department of Clinical Neuroscience; Center for Psychiatry Research; Karolinska Institutet; Stockholm Sweden
| | - Christer Halldin
- Department of Clinical Neuroscience; Center for Psychiatry Research; Karolinska Institutet; Stockholm Sweden
| |
Collapse
|
23
|
Akin A, Barrila MT, Brandt TA, Dechert-Schmitt AMR, Dube P, Ford DD, Kamlet AS, Limberakis C, Pearsall A, Piotrowski DW, Quinn B, Rothstein S, Salan J, Wei L, Xiao J. A Scalable Route for the Regio- and Enantioselective Preparation of a Tetrazole Prodrug: Application to the Multi-Gram-Scale Synthesis of a PCSK9 Inhibitor. Org Process Res Dev 2017. [DOI: 10.1021/acs.oprd.7b00304] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
| | | | | | | | - Pascal Dube
- Nalas Engineering Services, Inc., 85 Westbrook Road, Centerbrook, Connecticut 06409, United States
| | - David D. Ford
- Nalas Engineering Services, Inc., 85 Westbrook Road, Centerbrook, Connecticut 06409, United States
| | | | | | - Andrew Pearsall
- Nalas Engineering Services, Inc., 85 Westbrook Road, Centerbrook, Connecticut 06409, United States
| | | | - Brian Quinn
- Nalas Engineering Services, Inc., 85 Westbrook Road, Centerbrook, Connecticut 06409, United States
| | - Sarah Rothstein
- Nalas Engineering Services, Inc., 85 Westbrook Road, Centerbrook, Connecticut 06409, United States
| | - Jerry Salan
- Nalas Engineering Services, Inc., 85 Westbrook Road, Centerbrook, Connecticut 06409, United States
| | | | | |
Collapse
|
24
|
Kinens A, Sejejs M, Kamlet AS, Piotrowski DW, Vedejs E, Suna E. Development of a Chiral DMAP Catalyst for the Dynamic Kinetic Resolution of Azole Hemiaminals. J Org Chem 2017; 82:869-886. [DOI: 10.1021/acs.joc.6b02955] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Artis Kinens
- Latvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006 Riga, Latvia
| | - Marcis Sejejs
- Latvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006 Riga, Latvia
- University of Latvia, Department of Chemistry, Jelgavas 1, LV-1004 Riga, Latvia
| | - Adam S. Kamlet
- Worldwide
Medicinal Chemistry, Pfizer, Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - David W. Piotrowski
- Worldwide
Medicinal Chemistry, Pfizer, Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Edwin Vedejs
- Latvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006 Riga, Latvia
| | - Edgars Suna
- Latvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006 Riga, Latvia
- University of Latvia, Department of Chemistry, Jelgavas 1, LV-1004 Riga, Latvia
| |
Collapse
|
25
|
Abstract
A versatile synthesis of pyridazine-based small molecule α-helix mimetics (A) is presented. Modular C-C, C-N, and C-O bond-forming reactions allow for the inclusion of a variety of aliphatic, basic, aromatic, and heteroaromatic side chain moieties. This robust synthesis is suitable for the preparation of small pyridazine-based libraries.
Collapse
Affiliation(s)
- Allyn T. Londregan
- Pfizer Medicine Design, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - David W. Piotrowski
- Pfizer Medicine Design, Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Liuqing Wei
- Pfizer Medicine Design, Eastern
Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
26
|
Piotrowski DW, Kamlet AS, Dechert-Schmitt AMR, Yan J, Brandt TA, Xiao J, Wei L, Barrila MT. Regio- and Enantioselective Synthesis of Azole Hemiaminal Esters by Lewis Base Catalyzed Dynamic Kinetic Resolution. J Am Chem Soc 2016; 138:4818-23. [DOI: 10.1021/jacs.6b00207] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- David W. Piotrowski
- Worldwide Medicinal Chemistry, Pfizer, Inc., Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Adam S. Kamlet
- Worldwide Medicinal Chemistry, Pfizer, Inc., Eastern
Point Road, Groton, Connecticut 06340, United States
| | | | - Jiangli Yan
- Worldwide Medicinal Chemistry, Pfizer, Inc., Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Thomas A. Brandt
- Chemical Research and Development, Pfizer, Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| | - Jun Xiao
- Worldwide Medicinal Chemistry, Pfizer, Inc., Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Liuqing Wei
- Worldwide Medicinal Chemistry, Pfizer, Inc., Eastern
Point Road, Groton, Connecticut 06340, United States
| | - Mark T. Barrila
- Chemical Research and Development, Pfizer, Inc., Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
27
|
Hoang HN, Song K, Hill TA, Derksen DR, Edmonds DJ, Kok WM, Limberakis C, Liras S, Loria PM, Mascitti V, Mathiowetz AM, Mitchell JM, Piotrowski DW, Price DA, Stanton RV, Suen JY, Withka JM, Griffith DA, Fairlie DP. Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists. J Med Chem 2015; 58:4080-5. [PMID: 25839426 DOI: 10.1021/acs.jmedchem.5b00166] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Cyclic constraints are incorporated into an 11-residue analogue of the N-terminus of glucagon-like peptide-1 (GLP-1) to investigate effects of structure on agonist activity. Cyclization through linking side chains of residues 2 and 5 or 5 and 9 produced agonists at nM concentrations in a cAMP assay. 2D NMR and CD spectra revealed an N-terminal β-turn and a C-terminal helix that differentially influenced affinity and agonist potency. These structures can inform development of small molecule agonists of the GLP-1 receptor to treat type 2 diabetes.
Collapse
Affiliation(s)
- Huy N Hoang
- †Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia
| | | | - Timothy A Hill
- †Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia
| | | | | | - W Mei Kok
- †Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia
| | | | | | | | | | | | - Justin M Mitchell
- †Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia
| | | | | | | | - Jacky Y Suen
- †Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia
| | | | | | - David P Fairlie
- †Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia
| |
Collapse
|
28
|
Casimiro-Garcia A, Piotrowski DW, Ambler C, Arhancet GB, Banker ME, Banks T, Boustany-Kari CM, Cai C, Chen X, Eudy R, Hepworth D, Hulford CA, Jennings SM, Loria PM, Meyers MJ, Petersen DN, Raheja NK, Sammons M, She L, Song K, Vrieze D, Wei L. Identification of (R)-6-(1-(4-Cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic Acid, a Highly Potent and Selective Nonsteroidal Mineralocorticoid Receptor Antagonist. J Med Chem 2014; 57:4273-88. [DOI: 10.1021/jm500206r] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Affiliation(s)
- Agustin Casimiro-Garcia
- Pfizer Worldwide Research and Development, 200 CambridgePark Drive, Cambridge, Massachusetts 02140, United States
| | - David W. Piotrowski
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Catherine Ambler
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Graciela B. Arhancet
- Pfizer Worldwide Medicinal Chemistry, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Mary Ellen Banker
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Tereece Banks
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Carine M. Boustany-Kari
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Cuiman Cai
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Xiangyang Chen
- Pfizer Worldwide Medicinal Chemistry, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Rena Eudy
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - David Hepworth
- Pfizer Worldwide Research and Development, 200 CambridgePark Drive, Cambridge, Massachusetts 02140, United States
| | - Catherine A. Hulford
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Sandra M. Jennings
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Paula M. Loria
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Marvin J. Meyers
- Pfizer Worldwide Medicinal Chemistry, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States
| | - Donna N. Petersen
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Neil K. Raheja
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Matthew Sammons
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Li She
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kun Song
- Pfizer Worldwide Research and Development, 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Derek Vrieze
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Liuqing Wei
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
29
|
Futatsugi K, Piotrowski DW, Casimiro-Garcia A, Robinson S, Sammons M, Loria PM, Banker ME, Petersen DN, Schmidt NJ. Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists. Bioorg Med Chem Lett 2013; 23:6239-42. [DOI: 10.1016/j.bmcl.2013.09.099] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2013] [Accepted: 09/30/2013] [Indexed: 11/28/2022]
|
30
|
Kamlet AS, Préville C, Farley KA, Piotrowski DW. Regioselective hydroarylations and parallel kinetic resolution of Vince lactam. Angew Chem Int Ed Engl 2013; 52:10607-10. [PMID: 23956102 DOI: 10.1002/anie.201304818] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2013] [Indexed: 01/08/2023]
Abstract
Two regioselective and complementary hydroarylation reactions of an unsymmetrical cyclic olefin have been developed. The products can be transformed in one step into constrained γ-amino acids. Regioselective arylation of Vince lactam is controlled by the choice of phosphine ligand enantiomer and the substituent on the amide nitrogen atom. The method was extended to a general regiodivergent parallel kinetic resolution of the racemic lactam.
Collapse
Affiliation(s)
- Adam S Kamlet
- Worldwide Medicinal Chemistry, Pfizer Inc. Eastern Point Road, Groton, CT 06340 (USA).
| | | | | | | |
Collapse
|
31
|
Kamlet AS, Préville C, Farley KA, Piotrowski DW. Regioselective Hydroarylations and Parallel Kinetic Resolution of Vince Lactam. Angew Chem Int Ed Engl 2013. [DOI: 10.1002/ange.201304818] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
32
|
Sammons M, Jennings SM, Herr M, Hulford CA, Wei L, Hallissey JF, Kiser EJ, Wright SW, Piotrowski DW. Synthesis of a cis 2,5-Disubstituted Morpholine by De-epimerization: Application to the Multigram Scale Synthesis of a Mineralocorticoid Antagonist. Org Process Res Dev 2013. [DOI: 10.1021/op400101p] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- Matthew Sammons
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - Sandra M. Jennings
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - Michael Herr
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - Catherine A. Hulford
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - Liuqing Wei
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - James F. Hallissey
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - E. Jason Kiser
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - Stephen W. Wright
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| | - David W. Piotrowski
- Pfizer Worldwide Research and Development, Groton,
Connecticut 06340, United States
| |
Collapse
|
33
|
Londregan AT, Piotrowski DW, Futatsugi K, Warmus JS, Boehm M, Carpino PA, Chin JE, Janssen AM, Roush NS, Buxton J, Hinchey T. Discovery of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as potent agonists of TGR5 via sequential combinatorial libraries. Bioorg Med Chem Lett 2013; 23:1407-11. [DOI: 10.1016/j.bmcl.2012.12.076] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2012] [Revised: 12/17/2012] [Accepted: 12/21/2012] [Indexed: 01/22/2023]
|
34
|
Piotrowski DW, Futatsugi K, Warmus JS, Orr STM, Freeman-Cook KD, Londregan AT, Wei L, Jennings SM, Herr M, Coffey SB, Jiao W, Storer G, Hepworth D, Wang J, Lavergne SY, Chin JE, Hadcock JR, Brenner MB, Wolford AC, Janssen AM, Roush NS, Buxton J, Hinchey T, Kalgutkar AS, Sharma R, Flynn DA. Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists. ACS Med Chem Lett 2013; 4:63-8. [PMID: 24900564 DOI: 10.1021/ml300277t] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2012] [Accepted: 11/05/2012] [Indexed: 12/31/2022] Open
Abstract
Takeda G-protein-coupled receptor 5 (TGR5) represents an exciting biological target for the potential treatment of diabetes and metabolic syndrome. A new class of high-throughput screening (HTS)-derived tetrahydropyrido[4,3-d]pyrimidine amide TGR5 agonists is disclosed. We describe our effort to identify an orally available agonist suitable for assessment of systemic TGR5 agonism. This effort resulted in identification of 16, which had acceptable potency and pharmacokinetic properties to allow for in vivo assessment in dog. A key aspect of this work was the calibration of human and dog in vitro assay systems that could be linked with data from a human ex vivo peripheral blood monocyte assay that expresses receptor at endogenous levels. Potency from the human in vitro assay was also found to correlate with data from an ex vivo human whole blood assay. This calibration exercise provided confidence that 16 could be used to drive plasma exposures sufficient to test the effects of systemic activation of TGR5.
Collapse
Affiliation(s)
- David W. Piotrowski
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Kentaro Futatsugi
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Joseph S. Warmus
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Suvi T. M. Orr
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | | | - Allyn T. Londregan
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Liuqing Wei
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Sandra M. Jennings
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Michael Herr
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Steven B. Coffey
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Wenhua Jiao
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Gregory Storer
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - David Hepworth
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Jian Wang
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Sophie Y. Lavergne
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Janice E. Chin
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - John R. Hadcock
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Martin B. Brenner
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Angela C. Wolford
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Ann M. Janssen
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Nicole S. Roush
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Joanne Buxton
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Terri Hinchey
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Amit S. Kalgutkar
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Raman Sharma
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| | - Declan A. Flynn
- Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
| |
Collapse
|
35
|
Affiliation(s)
- Jana Polívková
- a Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc. , Groton , Connecticut , USA
| | - David W. Piotrowski
- a Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc. , Groton , Connecticut , USA
| |
Collapse
|
36
|
Futatsugi K, Bahnck KB, Brenner MB, Buxton J, Chin JE, Coffey SB, Dubins J, Flynn D, Gautreau D, Guzman-Perez A, Hadcock JR, Hepworth D, Herr M, Hinchey T, Janssen AM, Jennings SM, Jiao W, Lavergne SY, Li B, Li M, Munchhof MJ, Orr STM, Piotrowski DW, Roush NS, Sammons M, Stevens BD, Storer G, Wang J, Warmus JS, Wei L, Wolford AC. Optimization of triazole-based TGR5 agonists towards orally available agents. Med Chem Commun 2013. [DOI: 10.1039/c2md20174g] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
With the challenge of striking the balance of TGR5 potency and clearance, the screening strategy as well as medicinal chemistry strategy are discussed in this article.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Declan Flynn
- Pfizer Worldwide Research and Development
- Groton
- USA
| | | | | | | | | | - Michael Herr
- Pfizer Worldwide Research and Development
- Groton
- USA
| | | | | | | | - Wenhua Jiao
- Pfizer Worldwide Research and Development
- Groton
- USA
| | | | - Bryan Li
- Pfizer Worldwide Research and Development
- Groton
- USA
| | - Mei Li
- Pfizer Worldwide Research and Development
- Groton
- USA
| | | | | | | | | | | | | | | | - Jian Wang
- Pfizer Worldwide Research and Development
- Groton
- USA
| | | | - Liuqing Wei
- Pfizer Worldwide Research and Development
- Groton
- USA
| | | |
Collapse
|
37
|
Shao Q, Chen J, Tu M, Piotrowski DW, Huang Y. Enantioselective synthesis of 1,2,4-triazolines catalyzed by a cinchona alkaloid-derived organocatalyst. Chem Commun (Camb) 2013; 49:11098-100. [DOI: 10.1039/c3cc46757k] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
38
|
Sharma R, Sun H, Piotrowski DW, Ryder TF, Doran SD, Dai H, Prakash C. Metabolism, Excretion, and Pharmacokinetics of ((3,3-Difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a Dipeptidyl Peptidase Inhibitor, in Rat, Dog and Human. Drug Metab Dispos 2012; 40:2143-61. [DOI: 10.1124/dmd.112.047316] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
39
|
Affiliation(s)
- David W. Piotrowski
- Pfizer Worldwide Medicinal Chemistry, Eastern Point Road, Groton,
Connecticut 06340, United States
| |
Collapse
|
40
|
Abstract
A new and useful procedure for the macrocyclization of linear peptides is described. The natural amino acid side chains of tyrosine (phenol), lysine (alkylamine), and histidine (imidazole) react in an intramolecular fashion with a pendent pyridine-N-oxide-carboxamide, which is selectively activated by the phosphonium salt, PyBroP. The reaction is mild, rapid, and efficient with a potentially large substrate scope. Multiple examples are provided with full characterization and analyses, including a novel aza-variant of the C-O-D ring system of vancomycin.
Collapse
Affiliation(s)
- Allyn T Londregan
- CVMED Medicinal Chemistry, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, USA.
| | | | | | | | | |
Collapse
|
41
|
|
42
|
Boos C, Bowles DM, Cai C, Casimiro-Garcia A, Chen X, Hulford CA, Jennings SM, Jason Kiser E, Piotrowski DW, Sammons M, Wade RA. Synthesis and cross coupling of a highly substituted 2-pyridylboronate: application to the large scale synthesis of a mineralocorticoid antagonist. Tetrahedron Lett 2011. [DOI: 10.1016/j.tetlet.2011.10.052] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
43
|
Eudy RJ, Sahasrabudhe V, Sweeney K, Tugnait M, King-Ahmad A, Near K, Loria P, Banker ME, Piotrowski DW, Boustany-Kari CM. The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism. J Transl Med 2011; 9:180. [PMID: 22017794 PMCID: PMC3305907 DOI: 10.1186/1479-5876-9-180] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2011] [Accepted: 10/21/2011] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Accumulating evidence supports the role of the mineralocorticoid receptor (MR) in the pathogenesis of diabetic nephropathy. These findings have generated renewed interest in novel MR antagonists with improved selectivity against other nuclear hormone receptors and a potentially reduced risk of hyperkalemia. Characterization of novel MR antagonists warrants establishing translatable biomarkers of activity at the MR receptor. We assessed the translatability of urinary sodium to potassium ratio (Na+/K+) and plasma aldosterone as biomarkers of MR antagonism using eplerenone (Inspra®), a commercially available MR antagonist. Further we utilized these biomarkers to demonstrate antagonism of MR by PF-03882845, a novel compound. METHODS The effect of eplerenone and PF-03882845 on urinary Na+/K+ and plasma aldosterone were characterized in Sprague-Dawley rats and spontaneously hypertensive rats (SHR). Additionally, the effect of eplerenone on these biomarkers was determined in healthy volunteers. Drug exposure-response data were modeled to evaluate the translatability of these biomarkers from rats to humans. RESULTS In Sprague-Dawley rats, eplerenone elicited a rapid effect on urinary Na+/K+ yielding an EC50 that was within 5-fold of the functional in vitro IC50. More importantly, the effect of eplerenone on urinary Na+/K+ in healthy volunteers yielded an EC50 that was within 2-fold of the EC50 generated in Sprague-Dawley rats. Similarly, the potency of PF-03882845 in elevating urinary Na+/K+ in Sprague-Dawley rats was within 3-fold of its in vitro functional potency. The effect of MR antagonism on urinary Na+/K+ was not sustained chronically; thus we studied the effect of the compounds on plasma aldosterone following chronic dosing in SHR. Modeling of drug exposure-response data for both eplerenone and PF-03882845 yielded EC50 values that were within 2-fold of that estimated from modeling of drug exposure with changes in urinary sodium and potassium excretion. Importantly, similar unbound concentrations of eplerenone in humans and SHR rats yielded the same magnitude of elevations in aldosterone, indicating a good translatability from rat to human. CONCLUSIONS Urinary Na+/K+ and plasma aldosterone appear to be translatable biomarkers of MR antagonism following administration of single or multiple doses of compound, respectively. TRIAL REGISTRATION For clinical study reference EE3-96-02-004, this study was completed in 1996 and falls out scope for disclosure requirements. Clinical study reference A6141115: http://clinicaltrials.gov, http://NIHclinicaltrails.gov; NCTID: NCT00990223.
Collapse
Affiliation(s)
- Rena J Eudy
- Department of Cardiovascular, Metabolic, and Endocrine Diseases, Pfizer, Eastern Point Road, Groton, CT, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Dow RL, Li JC, Pence MP, Gibbs EM, LaPerle JL, Litchfield J, Piotrowski DW, Munchhof MJ, Manion TB, Zavadoski WJ, Walker GS, McPherson RK, Tapley S, Sugarman E, Guzman-Perez A, DaSilva-Jardine P. Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1. ACS Med Chem Lett 2011; 2:407-12. [PMID: 24900321 DOI: 10.1021/ml200051p] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2011] [Accepted: 03/15/2011] [Indexed: 12/24/2022] Open
Abstract
Acyl-CoA:diacylglycerol acyltransferase-1 (DGAT-1) catalyzes the final committed step in the biosynthesis of triglycerides. DGAT-1 knockout mice have been shown to be resistant to diet-induced obesity and have increased insulin sensitivity. Thus, inhibition of DGAT-1 may represent an attractive target for the treatment of obesity or type II diabetes. Herein, we report the discovery and characterization of a potent and selective DGAT-1 inhibitor PF-04620110 (3). Compound 3 inhibits DGAT-1 with an IC50 of 19 nM and shows high selectivity versus a broad panel of off-target pharmacologic end points. In vivo DGAT-1 inhibition has been demonstrated through reduction of plasma triglyceride levels in rodents at doses of ≥0.1 mg/kg following a lipid challenge. On the basis of this pharmacologic and pharmacokinetic profile, compound 3 has been advanced to human clinical studies.
Collapse
Affiliation(s)
- Robert L. Dow
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| | - Jian-Cheng Li
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| | - Michael P. Pence
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| | - E. Michael Gibbs
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| | - Jennifer L. LaPerle
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| | - John Litchfield
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| | - David W. Piotrowski
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| | - Michael J. Munchhof
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| | - Tara B. Manion
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| | - William J. Zavadoski
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| | - Gregory S. Walker
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| | - R. Kirk McPherson
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| | - Susan Tapley
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| | - Eliot Sugarman
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| | - Angel Guzman-Perez
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| | - Paul DaSilva-Jardine
- Pfizer Global Research and Development, Groton, Connecticut 06340, United States
| |
Collapse
|
45
|
Andrews KM, Beebe DA, Benbow JW, Boyer DA, Doran SD, Hui Y, Liu S, McPherson RK, Neagu C, Parker JC, Piotrowski DW, Schneider SR, Treadway JL, VanVolkenberg MA, Zembrowski WJ. 1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes. Bioorg Med Chem Lett 2011; 21:1810-4. [DOI: 10.1016/j.bmcl.2011.01.055] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2010] [Revised: 01/13/2011] [Accepted: 01/14/2011] [Indexed: 10/18/2022]
|
46
|
Denmark SE, Edwards JP, Weber T, Piotrowski DW. Organocerium additions to proline-derived hydrazones: synthesis of enantiomerically enriched amines. ACTA ACUST UNITED AC 2010. [DOI: 10.1016/j.tetasy.2010.04.042] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
47
|
|
48
|
|
49
|
Balan G, Bauman J, Bhattacharya S, Castrodad M, Healy DR, Herr M, Humphries P, Jennings S, Kalgutkar AS, Kapinos B, Khot V, Lazarra K, Li M, Li Y, Neagu C, Oliver R, Piotrowski DW, Price D, Qi H, Simmons HA, Southers J, Wei L, Zhang Y, Paralkar VM. The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorg Med Chem Lett 2009; 19:3328-32. [PMID: 19442519 DOI: 10.1016/j.bmcl.2009.04.044] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2009] [Revised: 04/06/2009] [Accepted: 04/08/2009] [Indexed: 11/26/2022]
Abstract
The design and profile of a series of zwitterionic calcium sensing receptor negative allosteric modulators is described. Evaluation of key analogues using a rat model demonstrate a robust response, significantly improved potency over ronacaleret and have the potential as an oral, anabolic treatment for osteoporosis.
Collapse
Affiliation(s)
- Gayatri Balan
- Pfizer Global Research and Development, Groton/New London Laboratories, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Acker BA, Jacobsen EJ, Rogers BN, Wishka DG, Reitz SC, Piotrowski DW, Myers JK, Wolfe ML, Groppi VE, Thornburgh BA, Tinholt PM, Walters RR, Olson BA, Fitzgerald L, Staton BA, Raub TJ, Krause M, Li KS, Hoffmann WE, Hajos M, Hurst RS, Walker DP. Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg Med Chem Lett 2008; 18:3611-5. [PMID: 18490160 DOI: 10.1016/j.bmcl.2008.04.070] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2008] [Revised: 04/25/2008] [Accepted: 04/28/2008] [Indexed: 11/17/2022]
Abstract
A novel alpha7 nAChR agonist, N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (3a, PHA-709829), has been identified for the potential treatment of cognitive deficits in schizophrenia. The compound shows potent and selective alpha7 in vitro activity, excellent brain penetration, good rat oral bioavailability and robust in vivo efficacy in a rat auditory sensory gating model.
Collapse
Affiliation(s)
- Brad A Acker
- Neuroscience Research, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|